César Agustín Ramírez-Díaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
César Agustín Ramírez-Díaz has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Angel León-Buitimea
Tecnológico de Monterrey, Instituto de Investigación sobre Obesidad
1 shared publication - Cesar R. Garza-Cárdenas
Facultad de Ciencias Químicas, Universidad Autónoma de Nuevo León (UANL), San Nicolás de los Garza 66455, Mexico
1 shared publication - José Rubén Morones-Ramírez
Universidad Autonóma de Nuevo León
1 shared publication - Martha Ulloa-Ramírez
Centro Universitario de Tonalá, Universidad de Guadalajara (UDG), Guadalajara 45425, Mexico
1 shared publication - María Fernanda Román-García
Centro de Estudios Científicos y Tecnológicos No. 9 “Juan de Dios Bátiz”, Instituto Politécnico Nacional, Miguel Hidalgo, Ciudad de México 11400, Mexico
1 shared publication
Latest Publications
- Open Access
- 12 June 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (6) , 794
Nanomaterials-Based Combinatorial Therapy as a Strategy to Combat Antibiotic Resistance
Since the discovery of antibiotics, humanity has been able to cope with the battle against bacterial infections. However, the inappropriate use of antibiotics, the lack of innovation in therapeutic agents, and other factors have allowed the emergence of new bacterial strains resistant to multiple antibiotic treatments, causing a crisis in the health sector. Furthermore, the World Health Organization has listed a series of pathogens (ESKAPE group) that have acquired new and varied resistance to different antibiotics families. Therefore, the scientific community has prioritized designing and developing novel treatments to combat these ESKAPE pathogens and other emergent multidrug-resistant bacteria. One of the solutions is the use of combinatorial therapies. Combinatorial therapies seek to enhance the effects of individual treatments at lower doses, bringing the advantage of being, in most cases, much less harmful to patients. Among the new developments in combinatorial therapies, nanomaterials have gained significant interest. Some of the most promising nanotherapeutics include polymers, inorganic nanoparticles, and antimicrobial peptides due to their bactericidal and nanocarrier properties. Therefore, this review focuses on discussing the state-of-the-art of the most significant advances and concludes with a perspective on the future developments of nanotherapeutic combinatorial treatments that target bacterial infections.
- 12 June 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (6) , 794
Open AccessNanomaterials-Based Combinatorial Therapy as a Strategy to Combat Antibiotic Resistance
Since the discovery of antibiotics, humanity has been able to cope with the battle against bacterial infections. However, the inappropriate use of antibiotics, the lack of innovation in therapeutic agents, and other factors have allowed the emergence of new bacterial strains resistant to multiple antibiotic treatments, causing a crisis in the health sector. Furthermore, the World Health Organization has listed a series of pathogens (ESKAPE group) that have acquired new and varied resistance to different antibiotics families. Therefore, the scientific community has prioritized designing and developing novel treatments to combat these ESKAPE pathogens and other emergent multidrug-resistant bacteria. One of the solutions is the use of combinatorial therapies. Combinatorial therapies seek to enhance the effects of individual treatments at lower doses, bringing the advantage of being, in most cases, much less harmful to patients. Among the new developments in combinatorial therapies, nanomaterials have gained significant interest. Some of the most promising nanotherapeutics include polymers, inorganic nanoparticles, and antimicrobial peptides due to their bactericidal and nanocarrier properties. Therefore, this review focuses on discussing the state-of-the-art of the most significant advances and concludes with a perspective on the future developments of nanotherapeutic combinatorial treatments that target bacterial infections.